Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Biocept To Present At LD Micro Main Event Wednesday, Oct. 13, 2021 At 2 p.m. EDT
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the LD Micro Main Event on
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord.
Biocept To Present Data At RAS-Targeted Drug Development Summit Showing Ability Of Its Switch-BlockerTM Technology To Detect Rare Cancer Mutations; Shares Spike Higher
Biocept (NASDAQ:BIOC), a leading provider of molecular diagnostic assays and services, will present data on its Target Selector™ assay formats for the ultra-sensitive detection of KRAS mutations using
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
38 Stocks Moving In Friday’s Mid-Day Session
Gainers
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 175% to $17.33. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
22 Stocks Moving in Friday’s Pre-Market Session
Gainers
GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society of Medicine General Assembly.
Investors React Positively To Study Data Of Biocept’s Cerebrospinal Fluid Assay
Biocept Inc (NASDAQ: BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide.
Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.
Biocept’s CNSide Assay Identifies Tumor Cells And Actionable Treatment Biomarkers From Cerebrospinal Fluid in Patients With Metastatic Non-Small Cell Lung Cancer
Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Study to be presented at the Society for